Periocular Pyogenic Granuloma : No BRAF V600E Mutation скачать в хорошем качестве

Periocular Pyogenic Granuloma : No BRAF V600E Mutation

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,[email protected], https://plus.google.com/communities/1... , ,https://plus.google.com/u/0/+Alexandr... ,    / @otolaryngologistorlent-med3259   ,    / @alexandrosg.sfakianakis4746   , https://twitter.com/g_orl?lang=el,   / alexandrossfakianakis  , No BRAF V600E Mutation Identified in 28 Periocular Pyogenic Granuloma by Li, Guosheng; Adams, Emily; Eshleman, James R.; Eberhart, Charles G. via Ophthalmic Plastic & Reconstructive Surgery - Published Ahead-of-Print Purpose: BRAF V600E mutations were recently identified in some pyogenic granulomas of skin, particularly lesions arising in patients with port wine stains. In this study, the authors analyzed BRAF gene status in 28 periocular pyogenic granulomas to determine its role in their pathogenesis. Methods: Retrospective review of ophthalmic pathology archives from 2007 to 2016 was used to identify pyogenic granulomas of the conjunctiva, eyelid, and orbit. Three eyelid nevi were also analyzed as positive controls. BRAF V600E status was assessed by pyrosequencing of DNA extracted from excess formalin-fixed, paraffin-embedded surgical material. Results: Microscopic examination of the periocular pyogenic granuloma specimens revealed proliferative vascular lesions, with radiating capillary channels surrounded by variable degrees of acute and chronic inflammation. Sequencing did not identify a BRAF V600E mutation in any of the 28 sporadic pyogenic granulomas, including 13 on the eyelid. In contrast, mutation analyses performed in parallel in melanocytic nevi of the eyelid identified BRAF V600E alterations in all 3 cases. Conclusions: The lack of BRAF V600E mutations in 28 sporadic pyogenic granulomas of the conjunctiva and eyelid suggests that such alterations are not a common driver in the pathogenesis of these periocular vascular lesions. Accepted for publication December 22, 2017. The study was funded in part by an unrestricted grant from Research to Prevent Blindness. The authors have no conflicts of interest to disclose. Address correspondence and reprint requests to Charles G. Eberhart, M.D., Ph.D., 720 Rutland Ave, Ross Bldg 558, Baltimore, MD 21205. E-mail: [email protected] © 2018 by The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc., All rights reserved. - video upload powered by https://www.TunesToTube.com